ArticleJournal of neurointerventional surgery2025
Off-label in-silico flow diverter performance assessment in posterior communicating artery aneurysms.
Article in Journal of neurointerventional surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ensuring the quality of in silico evidence: application to medical devices.Briefings in bioinformatics · 2026Article
- An Anatomy-Guided, Stepwise Microsurgical Reconstruction of a Posteriorly Projecting ICA-PCoA Aneurysm Beneath the Optic Apparatus: A Detailed Operative Sequence.Diagnostics (Basel, Switzerland) · 2026Article
- Key influencers in an aneurysmal thrombosis model: A sensitivity analysis and validation study.APL bioengineering · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe posterior communicating artery (PComA) is among the most common intracranial aneurysm locations, but flow diverter (FD) treatment with the widely used pipeline embolization device (PED) remains an off-label treatment that is not well understood. PComA aneurysm flow diversion is complicated by the presence of fetal posterior circulation (FPC), which has an estimated prevalence of 4-29% and is more common in people of black (11.5%) than white (4.9%) race. We present the FD-PComA in-silico trial (IST) into FD treatment performance in PComA aneurysms. ISTs use computational modeling and simulation in cohorts of virtual patients to evaluate medical device performance.
methodsWe modeled FD treatment in 118 virtual patients with 59 distinct PComA aneurysm anatomies, using computational fluid dynamics to assess post-treatment outcome. Boundary conditions were prescribed to model the effects of non-fetal and FPC, allowing for comparison between these subgroups.
resultsFD-PComA predicted reduced treatment success in FPC patients, with an average aneurysm space and time-averaged velocity reduction of 67.8% for non-fetal patients and 46.5% for fetal patients (P
conclusionsFD-PComA had significantly lower treatment success rates in PComA aneurysm patients with FPC. We suggest that FPC patients should be treated with an alternative to single PED flow diversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.